SecBot SecBot
8-K ·Filed Aug 4, 2026

SRTA

Strata Critical Medical, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001628280-26-052152
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and strong organic Clinical growth are the key catalysts. Monitor the Q3 earnings call for updates on the integration of the three Q2 acquisitions and the Statline customer transition, which could drive further upside to estimates. The cash burn from M&A is a watch item, but the improving operating cash flow trajectory supports the growth narrative.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+20d
SRTA ▼ -3.59% at T+20d
LONG call ✗ call lost -3.59% · α vs SPY -2.35% · entry $5.57 → $5.37
Next anchor: T+60d tomorrow
Latest observation: T+57 -6.14% FF3 residual α
Entry = T+0 close
Aug 4, 2026
via day close
T+1d
+5.03%
call +5.03% · α +5.23%
$5.85
settled 3mo ago
T+5d
+8.26%
call +8.26% · α +8.36%
$6.03
settled 3mo ago
T+20d
-3.59%
call -3.59% · α -2.35%
$5.37
settled 8w ago
T+60d
Pending
tomorrow

Price Chart

Loading chart...

Executive Summary

Strata Critical Medical reported Q2 2026 revenue of $72.5M (+60.7% YoY), beating the $67.6M consensus, and a GAAP EPS loss of -$0.12, which is worse than the -$0.04 consensus. The headline GAAP net loss widened to -$10.5M from -$3.4M a year ago, driven by $5.0M in accelerated trademark amortization and a $10.5M non-cash revaluation of earn-out liabilities. However, the company raised its full-year 2026 revenue guidance to $285-295M (from $260-275M) and Adjusted EBITDA guidance to $33-35M (from $29-33M), signaling strong underlying operational momentum in its Clinical segment and successful M&A execution. The stock will likely focus on the raised guidance and record operating cash flow, offsetting the GAAP loss noise.

Key Financial Metrics

EPS
−$0.12
est −$0.04 · -200.0%
Revenue
$72.5M
est $67.6M · +7.3% · +60.7% YoY
Rating
in line
Guidance
$285M-$295M
raised
Free Cash Flow
$2.9M
Gross Margin
21%

Key Facts

  • Q2 2026 revenue of $72.5M, up 60.7% YoY and above $67.6M consensus.
  • GAAP net loss from continuing operations of -$10.5M, or -$0.12 per share, vs. -$3.4M loss a year ago.
  • Adjusted EBITDA of $7.9M, up 219.8% YoY, with margin expanding to 10.9% from 5.5%.
  • Raised full-year 2026 revenue guidance to $285-295M (from $260-275M) and Adjusted EBITDA guidance to $33-35M (from $29-33M).
  • Clinical revenue grew 22.6% sequentially; excluding acquisitions, organic Clinical revenue rose 15.1%.
  • Completed three bolt-on acquisitions in Q2 2026 and signed an agreement to take over Statline's organ placement customer relationships.
  • Operating cash flow of $5.7M and free cash flow before aircraft acquisitions of $2.9M, both records.
  • Cash and short-term investments fell to $22.8M from $58.8M at Q1 end, largely due to $34.8M in acquisition spending.

Financial Impact

Revenue guidance raised by $22.5M at midpoint; Adjusted EBITDA guidance raised by $3M at midpoint.

revenueadjusted_ebitdaoperating_cash_flowclinical_revenue

Risk Factors

  • GAAP net loss widened significantly due to non-cash charges, which may concern some investors.
  • Cash and short-term investments dropped sharply from $58.8M to $22.8M due to acquisition spending, raising liquidity questions if M&A continues at this pace.
  • Logistics gross margin declined 160 bps YoY to 18.4%, pressured by fuel costs and customer mix.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Health Services
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-052152
Document: srta-20260804.htm0001628280-26-052152
Document: 0001628280-26-052152-index-headers.html0001628280-26-052152
Document: 0001628280-26-052152-index.html0001628280-26-052152
Document: 0001628280-26-052152.txt0001628280-26-052152
8-K Data (Synthetic)0001628280-26-052152
10 reports for SRTA
Performance horizon
60% Hit rate @ T+1 3 of 5 directional calls Went positive at some point 4 of 5 best @ T+60▲ +36.75%Feb 28, 2026
Filters
Rows
Reports for SRTA — sortable, filterable
TypeNow
Oct 23, 2026
3d ago
Press Release
NEUTRAL ★ 1/10
$4.66awaiting T+1—$4.76 (+2.15%)
Oct 15, 2026
11d ago
SC 13D
BULLISH ★ 7/10
$4.54 $4.54· 0.00%▼ −0.42%$4.76 (+4.85%)
Oct 2, 2026
24d ago
144
NEUTRAL ★ 3/10
$4.73 $4.81▲ +1.69%▲ +1.02%$4.76 (+0.63%)
Aug 21, 2026
9w ago
Institutional Cluster
BULLISH ★ 5/10
$6.24 $5.97▼ −4.33%▼ −4.03%$4.76 (−23.72%)
Aug 4, 2026
11w ago
8-K
BULLISH ★ 7/10
$5.57 $5.85▲ +5.03%▲ +5.23%$4.76 (−14.54%)
Jul 21, 2026
13w ago
Press Release
NEUTRAL ★ 1/10
$5.08 $5.09▲ +0.20%▲ +1.43%$4.76 (−6.30%)
Jun 10, 2026
19w ago
Insider Cluster
BEARISH ★ 4/10
$5.49 $5.43▲ +1.09%▲ +1.63%$4.76 (+13.30%)
May 7, 2026
24w ago
Press Release
NEUTRAL ★ 2/10
$5.57 $5.66▲ +1.62%▲ +1.38%$4.76 (−14.54%)
Mar 3, 2026
33w ago
Press Release
BULLISH ★ 8/10
$4.80 $4.89▲ +1.88%▲ +1.11%$4.76 (−0.83%)
Feb 28, 2026
34w ago
Institutional Cluster
BULLISH ★ 6/10
$4.49 $4.80▲ +6.90%▲ +7.82%$4.76 (+6.01%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 2h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026